Vertex SVP Ambrose sells 357 VRTX shares

Vertex Pharmaceuticals senior vice president and chief accounting officer Kristen Ambrose reported an open-market sale of 357 shares of common stock at $483.36 per share.

Rhea-AI Filing Summary

Vertex Pharmaceuticals senior vice president and chief accounting officer Kristen Ambrose reported an open-market sale of 357 shares of common stock at $483.36 per share. After this transaction, she directly holds 6,624 shares. The sale was made under a pre-established, company-approved Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 357 shares

Net Sell 1 txn

Insider Ambrose Kristen

Role SVP & Chief Accounting Officer

Sold 357 shs ($173K)

Type	Security	Shares	Price	Value
Sale	Common Stock	357	$483.36	$173K

Holdings After Transaction: Common Stock — 6,624 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VRTX executive Kristen Ambrose report?

Kristen Ambrose reported selling 357 shares of Vertex Pharmaceuticals common stock in an open-market transaction. The shares were sold at a price of $483.36 each, and the transaction was disclosed on a Form 4 insider trading report.

At what price were the VRTX shares sold in Kristen Ambrose’s Form 4 filing?

The reported sale price was $483.36 per share of Vertex Pharmaceuticals common stock. This price reflects the open-market transaction disclosed, giving investors a clear view of the execution level for this particular insider sale.

How many VRTX shares does Kristen Ambrose own after this Form 4 sale?

After the reported transaction, Kristen Ambrose directly owns 6,624 shares of Vertex Pharmaceuticals common stock. This post-transaction holding is shown in the Form 4 and represents her remaining direct ownership stake following the sale.

Was the VRTX insider sale by Kristen Ambrose under a 10b5-1 trading plan?

Yes. The filing states the transaction was made under Ms. Ambrose’s company-approved Rule 10b5-1 trading plan. Such plans pre-arrange trades, helping separate routine diversification or liquidity needs from discretionary timing decisions.

What role does Kristen Ambrose hold at Vertex Pharmaceuticals (VRTX)?

Kristen Ambrose serves as senior vice president and chief accounting officer at Vertex Pharmaceuticals. Her Form 4 filing reflects an insider sale of company common stock, which must be reported because of her executive officer status and access to material information.

Does the VRTX Form 4 show a buy or sell transaction by Kristen Ambrose?

The Form 4 reports a sell transaction. Specifically, it shows an open-market sale of 357 shares of Vertex Pharmaceuticals common stock, categorized with transaction code “S,” which denotes a sale in an open-market or private transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:10 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ambrose Kristen

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		S(1)		357	D	$483.36	6,624	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.